CURO Biosciences Pvt. Ltd., operating as ErlySign, has raised ₹16 crore in pre-Series A funding from prominent investor Ashish Kacholia. Facilitated by DerivativeSaint, a private equity and venture capital advisory firm, the investment underscores ErlySign’s mission to revolutionize early cancer detection.
The company’s biomarker-based test kit offers a groundbreaking solution for diagnosing oral precancerous conditions within 15 minutes using a non-invasive saliva sample. By addressing the challenges of traditional diagnostic methods—often painful, time-consuming, and costly—the test promises a swift, affordable, and painless alternative.
“Our initial studies have shown 100% specificity and 98.04% sensitivity,” said Shubhendra Singh Thakur, CEO and Founder of ErlySign. “The product, now in advanced clinical trials at multiple HCG sites, aims to transform cancer diagnostics and eliminate unnecessary biopsies.”
As reported by economictimes, the funding will expedite clinical trials, secure CDSCO approvals, and support market introduction. It will also facilitate R&D, patent filings, and team expansion. ErlySign is also exploring CRISPR miRNA technology to enable multi-cancer detection within 15–20 minutes using a single saliva sample—a move poised to redefine diagnostic precision and accessibility.